The doctors at Cardiovascular Specialists of Southwest Louisiana have performed almost every treatment or procedure in cardiology available anywhere in the world—except for heart transplantation—right here in Lake Charles, Louisiana. Being a part of many medical firsts in our region—heart catheterizations, dual-chamber pacemakers, and implantable defibrillators—Michael C. Turner, M.D. is no stranger to breaking new ground for cardiac patients in Southwest Louisiana.
As a general rule, people undergoing heart catheterizations in the United States do so with the procedure starting at the femoral artery found in the groin. However, local interventional cardiologist Dr. Thomas Mulhearn with Cardiovascular Specialists is using a new technique that accesses the pathway to the heart through the wrist. It’s called the transradial approach to cardiac catheterization, and he says it offers many benefits to patients.
Dr. Michael Turner MD, FACC, FSCCT, preventive cardiology specialist with Cardiovascular Specialists, has been appointed co -editor for the new CT section of the international online journal Echocardiography, the official publication of the Society of Cardiovascular Ultrasound.
An article submitted by Dr. Michael Turner MD, FACC, FSCCT, preventive cardiology specialist with Cardiovascular Specialists in Lake Charles was published last month in the medical journal Echocardiography.
February is American Heart Month, and since its inception in 1964, this annual observance has done much to increase awareness about cardiovascular disease and how to prevent it. As a result, improvements in heart disease prevalence and mortality rates are being made each year.
Patients can now get the same protection from sudden cardiac arrest as they would get with a defibrillator but through a less invasive procedure that does not touch their heart and blood vessels, thanks to the world's first and only commercially available subcutaneous implantable defibrillator (S-ICD).
Cardiovascular Specialists of Southwest Louisiana was selected as an investigative site for the PROMISE Trial, a study of the effectiveness of tests to detect coronary artery disease. Michael C. Turner, M.D., is principal investigator and Thomas J. Mulhearn IV, M.D., is co-investigator.